Prelude Therapeutics Incorporated (PRLD) Dividend History

Company News

• Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

  Prelude Therapeutics announced positive initial clinical data for its SMARCA2 degrader PRT3789 in a Phase 1 trial, showing promising anti-tumor activity and a generally well-tolerated safety profile in patients with SMARCA4-mutated cancers.

  GlobeNewswire Inc.
• New Strong Buy Stocks for January 25th

  S, ASAN, PRLD, EMKR and SNAP have been added to the Zacks Rank #1 (Strong Buy) List on January 25, 2023.

  Zacks Investment Research

  Featured Companies: ASAN S SNAP
• Morgan Stanley Downgrades Prelude Therapeutics: Here's What You Need To Know

  Morgan Stanley downgraded its rating of Prelude Therapeutics (NASDAQ:PRLD) to Underweight with a price target of $4.00, changing its price target from $10.00 to $4.00. Shares of Prelude Therapeutics are trading up 0.0% over the last 24 hours, at $4.37 per share. A move to $4.00 would account for a 8.47% decrease from the current share price. About Prelude Therapeutics Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. The company's pipeline includes four candidates currently in ...Full story available on Benzinga.com

  Benzinga
• Wall Street Breakfast: What Moved Markets

  Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks and U.S.

  Seeking Alpha

  Featured Companies: AAPL ALLO AMPY AMZN GOOG GOOGL HPE NKTX ORCL SCHW TSLA VYGR XENE